Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money. Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

Bubs share price: Citi says ‘buy’ and a capital raise is announced

The company's stock has today been put in a trading halt, as an announcement pending a planned capital raise is set to be revealed to the market.

Capital raise announced

Bubs’ (ASX: BUB) shares have today been put in a trading halt, as the fast-growing infant formula company revealed that it was planning on pursuing a capital raise.

Bubs now joins a raft of ASX-listed companies – including Afterpay, Zip, Westpac and the Bank of Queensland – tapping the markets for fresh capital.

While no specific details of the Bubs capital raise have been announced just yet – one can speculate that Bubs would likely used any funds derived from a potential capital raise to further ramp up its growth plans.

Indeed, FY19 already proved to be a record growth year for the young company: with gross revenue rising 154% to $46.8m. In step with this, and maybe even more impressively, Bubs China Net revenue grew 209% in FY19.

In line with this explosive growth profile, the Bubs share price has more than doubled in CY19 – rising 135% since January.

Practise trading Australian stocks with an IG demo account now

Bubs share price: Citi says ‘buy’

The announcement of a planned cap raise comes just one day after investment giant Citibank initiated coverage on the infant formula player: hitting Bubs (ASX: BUB) with a buy rating and a 12-month share price target of $1.40.

At Bubs’ (ASX: BUB) last traded price, this would imply potential upside of a little over 30%.

Centrally, Citi posits that Bubs is well-positioned to capitalise on the premiumisation trend sweeping the Chinese infant formula market (IMF) – and as a result of this – sees substantial top and bottom-line growth opportunities for the company in the coming years. Funds derived from the planned capital raise would likely help further any such plans.

In saying that, the investment bank has flagged a number of risks to their investment thesis, noting that an investment in Bubs remains 'high risk.' Fundamentally, these risks include the fact that Bubs remains loss-making, competition remains intense and the possibility that Bubs will be unable to adequately capitalise on the significant opportunities at hand.

Citi further points out that Bubs’ current valuation suggests that the market is expecting big things from the young company.

Ultimately, Citi believes that the prospect of Bubs’ fundamentals catching up with the market's current growth expectations by FY22 is not ‘unrealistic’ – as the company potentially transitions to profitability. On this front, the investment bank expects Bubs to achieve profitability in FY21 – with forecasted profits (core NPAT) of $10.4m.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Act on share opportunities today

Go long or short on thousands of international stocks with spread bets and CFDs.

  • Get full exposure for a comparatively small deposit
  • Trade on spreads from just 0.1%
  • Get greater order book visibility with direct market access

See opportunity on a stock?

Try a risk-free trade in your demo account, and see whether you’re on to something.

  • Log in to your demo
  • Take your position
  • See whether your hunch pays off

See opportunity on a stock?

Don’t miss your chance – upgrade to a live account to take advantage.

  • Trade a huge range of popular stocks
  • Analyse and deal seamlessly on fast, intuitive charts
  • See and react to breaking news in-platform

See opportunity on a stock?

Don’t miss your chance. Log in to take advantage while conditions prevail.

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Sunday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of spread betting and CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.